Drug Trial Radar · NCT05206890
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Jan 14, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- First Hospital of China Medical University; Cancer Hospital of Xinjiang Medical University; First Affiliated Hospital Xi'an Jiaotong University; Qingyuan People's Hospital; Zhejiang University; Panzhihua Central Hospital; Liangshan First People's Hospital; Guang'an people's hospital of Sichuan province; Affiliated Hospital of North Sichuan Medical College; Cancer Hospital of Guizhou Province; Guizhou International General Hospital; Yichang Central People's Hospital; Wuhan Fourth Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- First posted
- Jan 25, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
fluzoparib monotherapy or combination therapyDrug
patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of ≥ grade 3 Hematology related adverse event according to NCI CTCAE v5.0Time frame: 30 days after the last dose of fluzoparib
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.